In Vitro Cytotoxicity of Rare Earth Oxide Nanoparticles for Imaging Applications
Source abstract
Abstract
The in vitro cytotoxicity and cellular uptake of commercially available doped YVO 4 were evaluated in RAW 264.7 macrophages using the MTT assay. The results indicated that 20–50 nm diameter samarium‐doped YVO 4 showed significant toxicity at concentrations of 25 μg/mL and higher; samples of the same material functionalized with COOH showed less cytotoxicity. At concentrations of 25–100 μg/mL, 20–50 nm erbium‐doped YVO 4 showed less toxicity compared with 20–50 nm samarium‐doped YVO 4 . Ten nanometer samples showed no toxicity at concentrations of 100–600 μg/mL. The cytotoxicity of rare earth nanoparticles in macrophages is dependent, at least in part, on size and surface functionalization.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photoacoustic and Ultrasonic Imaging · Nanoparticles: synthesis and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Division of Biology Office of Science and Engineering Laboratories Center for Devices and Radiological Health U.S. Food and Drug Administration Silver Spring MD 20993
Joint Department of Biomedical Engineering UNC – Chapel Hill and North Carolina State University Raleigh NC 27965
Sun Innovations Inc Fremont CA 94539
References (41)
Show source-provided references
1. 10.1002/crat.20100046910.1002/crat.201000469 ↗
2. 10.1002/(SICI)1521-3765(19981102)4:11<2315::AID-CHEM2315>3.0.CO;2-E10.1002/(SICI)1521-3765(19981102)4:11<2315::AID-CHEM2315>3.0.CO;2-E ↗
3. 10.1021/ja038650110.1021/ja0386501 ↗
4. 10.12693/APhysPolA.120.29810.12693/APhysPolA.120.298 ↗
5. 10.1039/c0jm00031k10.1039/c0jm00031k ↗
6. 10.1016/j.jlumin.2011.03.03910.1016/j.jlumin.2011.03.039 ↗
7. 10.1016/S0167-577X(03)00237-410.1016/S0167-577X(03)00237-4 ↗
8. 10.1016/j.biomaterials.2011.07.05310.1016/j.biomaterials.2011.07.053 ↗
9. 10.1021/jp906394z10.1021/jp906394z ↗
10. 10.1021/bc200201e10.1021/bc200201e ↗
11. 10.1002/tox.2040210.1002/tox.20402 ↗
12. 10.1016/j.chemosphere.2009.10.05010.1016/j.chemosphere.2009.10.050 ↗
13. 10.1016/j.saa.2011.09.02710.1016/j.saa.2011.09.027 ↗
14. 10.1016/j.apsusc.2011.08.10610.1016/j.apsusc.2011.08.106 ↗
15. 10.1016/j.matlet.2011.08.01910.1016/j.matlet.2011.08.019 ↗
16. 10.1016/S0013-9351(87)80066-X10.1016/S0013-9351(87)80066-X ↗
17. 10.1039/c1dt10389j10.1039/c1dt10389j ↗
18. 10.1002/bip.2148810.1002/bip.21488 ↗
19. 10.1002/anie.20060297510.1002/anie.200602975 ↗
20. 10.1021/nn201896m10.1021/nn201896m ↗
21. Endotoxins and Medical Devices: The Significance of Dead Bacteria
22. 10.1016/j.ijpharm.2004.09.01810.1016/j.ijpharm.2004.09.018 ↗
23. 10.1186/1743-8977-6-1410.1186/1743-8977-6-14 ↗
24. 10.1039/b903306h10.1039/b903306h ↗
25. 10.1002/jat.138210.1002/jat.1382 ↗
26. 10.1364/OL.31.00285510.1364/OL.31.002855 ↗
27. 10.1007/s11426-011-4319-610.1007/s11426-011-4319-6 ↗
28. 10.1016/j.matchemphys.2010.09.06810.1016/j.matchemphys.2010.09.068 ↗
29. 10.1002/app.3396710.1002/app.33967 ↗
30. 10.1111/j.2042-7158.1989.tb06396.x10.1111/j.2042-7158.1989.tb06396.x ↗
31. 10.1002/jps.1035710.1002/jps.10357 ↗
32. 10.1021/ja810045y10.1021/ja810045y ↗
33. 10.1088/0957-4484/20/50/50560610.1088/0957-4484/20/50/505606 ↗
34. 10.1177/10915818980170040810.1177/109158189801700408 ↗
35. 10.1039/c1ra00586c10.1039/c1ra00586c ↗
36. 10.1016/j.actbio.2011.07.03310.1016/j.actbio.2011.07.033 ↗
37. 10.1165/ajrcmb.23.3.411210.1165/ajrcmb.23.3.4112 ↗
38. 10.1038/nnano.2008.11110.1038/nnano.2008.111 ↗
39. 10.1163/15685520777976821410.1163/156855207779768214 ↗
40. 10.1016/j.tiv.2009.06.01910.1016/j.tiv.2009.06.019 ↗
41. United States Pharmacopeial Convention “Transfusion and Infusion Assemblies and Similar Medical Devices ” Recognition Number 14‐305 USP 33:2010 United States Pharmacopeial Convention Rockville MD 2010.